Loading data for LBRX — first visit, this takes a few seconds.
LB Pharmaceuticals Inc (LBRX)
NasdaqGM: LBRX
· 实时价格 · USD
49.34
+1.82 (3.83%)
收盘价： Sep 04, 2026, 8:00 PM
49.34
+0.00%
盘后: 7:30 PM
股价、关键数字和最新消息，都在这一页。
LB Pharmaceuticals Inc（LBRX）股价、分析与数据
暂无数据
| 买价 | 32.42 |
| 市值 | 1.59B |
| 营收（TTM） | n/a |
| 净利润（TTM） | -85.7M |
| 0.00 | |
| -5.1 | |
| n/a | |
| -9.8 | |
| 市净率（TTM） | 4.26 |
| 市销率（TTM） | 0.00 |
| 财报日期 | Nov 12, 2026 |
| 卖价 | 57.43 |
| 成交量 | 205,855 |
| 20日均量 | 340,575 |
| 开盘价 | 47.47 |
| 前收盘价 | 47.52 |
| 日内区间 | 47.47 - 49.87 |
| 52周区间 | 13.36 - 50.16 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for...
公司完整简介财报意外
LB Pharmaceuticals Inc 已于 Aug 11, 2026 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -1.71 低于预期 -0.91, ， -Infinity% 同比下滑.
第 1 页，共 2 页